This clinical trial is focused on studying a type of cancer called Follicular Lymphoma, which is a form of non-Hodgkin lymphoma. The study involves patients who have been newly diagnosed with advanced stages of this disease. The treatment being tested combines two medications: Golcadomide and Rituximab. Golcadomide, also known by its code name CC-99282, is taken orally in capsule form, while Rituximab is administered as an infusion, meaning it is given directly into the bloodstream through a vein.

The purpose of the study is to evaluate the effectiveness and safety of this combination treatment. The main goal is to see if the treatment can achieve a Complete Metabolic Response (CMR), which means that after treatment, tests show no signs of cancer in the body. The study will also monitor for any side effects or adverse events, which are any negative impacts on health that occur during the treatment. These include any new side effects that appear after starting the treatment, known as Treatment-Emergent Adverse Events (TEAEs).

Participants in the study will receive the treatment over a period of time, and their response will be evaluated at different stages, such as 6 months and 12 months after starting the treatment. The study will also assess the overall response rate (ORR), which is the percentage of participants whose cancer shrinks or disappears, as well as progression-free survival (PFS) and overall survival (OS). PFS is the time from the start of treatment until the disease worsens or the patient passes away, while OS is the time from the start of treatment until the patient passes away. The study aims to provide valuable information on the potential benefits and risks of using Golcadomide and Rituximab together for treating advanced stage Follicular Lymphoma.